DAWN - NASDAQ

Day One Biopharmaceuticals, Inc.

DAWN·NASDAQ

$21.53

+0.0000%

HealthcareBiotechnology

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$2.22B

EPS-1.0400

P/E Ratio-20.70

Earnings Date05/13/2026

-103.76M

Operating Cash Flow

33%

3Y-6.0%

5Y+669.0%

10Y+2198.0%

174.65M

Investing Cash Flow

-176%

3Y-168.0%

5Y-189935.0%

10Y-

1.22M

Financing Cash Flow

-99%

3Y-99.0%

5Y-96.0%

10Y-96.0%

Day One Biopharmaceuticals, Inc. Cash Conversion Engine

DAWN · NASDAQ

FCF Components

Net Income-107.32M

Depreciation & Amortization3.48M

Stock-Based Compensation44.39M

Change in Working Capital-28.94M

Others-15.36M

Capital Expenditures-320.00K

Free Cash Flow-104.08M

Cash Flow Quality Analysis

FCF Conversion Rate

97.0%

Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.

CapEx Intensity

-0.3%

Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.

FCF Growth Trend

-29.6%

Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.

Working Capital Impact

-$28.94M

Moderate working capital outflow. Typical for growing businesses, but ensure it's supporting revenue growth, not inefficiency.

Cash Flow Quality Insight

Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.

Day One Biopharmaceuticals, Inc. Cash Flow Statement

DAWN • NASDAQ

Day One Biopharmaceuticals, Inc. Cash Flow Statement	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
OPERATING ACTIVITIES
Net Income	-107.3M	-95.5M	-188.9M	-142.2M	-72.8M	-43.8M	-17M
Depreciation & Amortization	3.5M	2M	383K	531K	199K	155K	0.0
Stock-Based Compensation	44.4M	48.3M	39.3M	27.2M	13.3M	526K	111K
Other Non-Cash Items	-15.4M	-59.4M	-7.1M	-2M	8M	30M	11.9M
Cash Taxes Paid	(0.0)	(1.9M)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)
Change in Working Capital	-28.9M	26.5M	9.4M	6.6M	2.7M	-357K	444K
Cash from Operating Activities	-103.8M	-78.1M	-146.9M	-109.9M	-48.5M	-13.5M	-4.5M
INVESTING ACTIVITIES
Investments in Property, Plant, and Equipment	-320K	-2.2M	-224K	-26K	-8M	-92K	(0.0)
Acquisitions, Net	(0.0)	(0.0)	(0.0)	(255K)	(0.0)	(0.0)	(0.0)
Purchase of Investments	-695.8M	-658.6M	-443.8M	-394.2M	(0.0)	(0.0)	(0.0)
Sale/Maturity of Investments	874.2M	393.9M	575.4M	139.2M	0.0	0.0	0.0
Other Investing Items	-3.5M	35.9M	-3M	-255K	0.0	0.0	0.0
Cash from Investing Activities	(174.6M)	-231M	(128.4M)	-255.1M	-8M	-92K	(0.0)
FINANCING ACTIVITIES
Net Issuance of Common Stock	1.2M	178.2M	161.4M	161.6M	167M	30M	0.0
Net Issuance of Debt	0.0	0.0	0.0	0.0	0.0	0.0	1M
Other Financing Items	0.0	25.1M	0.0	4.3M	318K	0.0	0.0
Cash from Financing Activities	1.2M	203.3M	164M	165.9M	297.1M	30M	30.9M
CASH FLOW SUMMARY
Net Change in Cash	72.1M	-105.8M	145.5M	-199M	240.6M	16.4M	26.4M
Cash at Beginning of Period	125M	230.8M	85.3M	284.3M	43.7M	27.3M	942K
Cash at End of Period	197.1M	125M	230.8M	85.3M	284.3M	43.7M	27.3M
Free Cash Flow	-104.1M	-80.3M	-150.1M	-109.9M	-56.5M	-13.6M	-4.5M

SEC Filings

DAWN - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	April 23, 2026	April 22, 2026	2026	View Filing
10-K/A 10-K/A 2025 FY (Amended) FY	April 17, 2026	December 31, 2025	2025	View Filing
8-K/A 8-K/A 2026 (Amended) N/A	March 09, 2026	January 06, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 06, 2026	March 06, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 02, 2026	March 02, 2026	2026	View Filing
10-K 10-K 2025 FY FY	February 24, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	February 24, 2026	February 24, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 12, 2026	January 11, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 06, 2026	January 06, 2026	2026	View Filing
8-K 8-K 2025 N/A	November 24, 2025	November 24, 2025	2025	View Filing

Showing 1 to 10 of 93 filings

Related Guides

Blog Categories

Continue your DAWN research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.